-
公开(公告)号：US09399673B2
公开(公告)日：2016-07-26
申请号：US13786206
申请日：2013-03-05
Applicant: Genentech, Inc. , AIMM Therapeutics B.V.
Inventor： Tim Beaumont , Mark Jeroen Kwakkenbos , Eric J. Brown , John Hiroshi Morisaki , Wouter L. W. Hazenbos , Sanjeev Mariathasan , Kimberly Kajihara , Yi Xia
IPC: C07K16/12
CPC classification number: G01N33/5091 , C07K16/1271 , C07K16/1278 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N33/6893 , G01N2469/10 , G01N2800/26
Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
-
公开(公告)号：US20160168232A9
公开(公告)日：2016-06-16
申请号：US13786206
申请日：2013-03-05
Applicant: Genentech, Inc. , AIMM Therapeutics B.V.
Inventor： Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Eric J. BROWN , John Hiroshi MORISAKI , Wouter L.W. HAZENBOS , Sanjeev MARIATHASAN , Kimberly KAJIHARA , Yi XIA
IPC: C07K16/12
CPC classification number: G01N33/5091 , C07K16/1271 , C07K16/1278 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N33/6893 , G01N2469/10 , G01N2800/26
Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
-
23.发明申请公开(公告)号：US20160060598A1
公开(公告)日：2016-03-03
申请号：US14836335
申请日：2015-08-26
Inventor： Hergen Spits , Ferenc A. Scheeren , Tim Beaumont , Sean A. Diehl
IPC: C12N5/0781
CPC classification number: C12N5/0635 , C07K16/00 , C12N2501/23 , C12N2501/231 , C12N2501/2321 , C12N2501/52 , C12N2501/60 , C12N2502/99 , C12N2510/02 , C12N2510/04
Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
Abstract translation: 本发明提供了影响抗体产生细胞的稳定性的方法，其包括直接或间接地影响所述抗体产生细胞内的BCL6和/或Blimp1表达产物的量。 还提供稳定的抗体产生细胞和细胞系，以及使用这种细胞和/或细胞系产生抗体的方法。
-
公开(公告)号：US20150376266A1
公开(公告)日：2015-12-31
申请号：US14728826
申请日：2015-06-02
Applicant: Genentech, Inc. , AIMM Therapeutics B.V.
Inventor： Tim BEAUMONT , Mark Jeroen KWAKKENBOS , Eric J. BROWN , John Hiroshi MORISAKI , Wouter L.W. HAZENBOS , Sanjeev MARIATHASAN , Kimberly KAJIHARA , Yi XIA
IPC: C07K16/12
CPC classification number: G01N33/5091 , C07K16/1271 , C07K16/1278 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N33/6893 , G01N2469/10 , G01N2800/26
Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。 提供了完全人类的结合化合物，可在人类个体中实现治疗应用。
-
公开(公告)号：US10774308B2
公开(公告)日：2020-09-15
申请号：US16114483
申请日：2018-08-28
Inventor： Hergen Spits
IPC: A61K38/00 , C07K16/00 , C12N5/18 , C12N5/0781
Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
-
Patent Agency Ranking
公开(公告)号：US20190023803A1
公开(公告)日：2019-01-24
申请号：US16068742
申请日：2017-01-06
Applicant: AIMM Therapeutics B.V.
Inventor： Hergen SPITS , Paula Maria Wilhelmina VAN HELDEN , Remko SCHOTTE , Wouter POS , Christien FATMAWATI , Danïel Michiel GO , Koen WAGNER , Julien Christian VILLAUDY
IPC: C07K16/28 , C07K14/705 , G01N33/574 , A61P35/00
Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
-
公开(公告)号：US20180371410A1
公开(公告)日：2018-12-27
申请号：US16114483
申请日：2018-08-28
Inventor： Hergen SPITS
IPC: C12N5/0781 , C07K16/00
CPC classification number: C12N5/0635 , C07K16/00 , C12N2501/23 , C12N2501/60
Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
-
公开(公告)号：US20180170998A1
公开(公告)日：2018-06-21
申请号：US15737924
申请日：2016-06-24
Applicant: AIMM THERAPEUTICS B.V.
Inventor： Hergen SPITS , Marijn Aletta GILLISSEN , Martijn KEDDE , Mette Deborah HAZENBERG , Paula Maria Wilhelmina van HELDEN , Wouter POS
IPC: C07K14/705 , C07K16/28 , G01N33/574
CPC classification number: C07K14/70596 , A61K38/00 , C07K14/435 , C07K16/2896 , C07K2317/732 , C07K2317/734 , G01N33/57426 , G01N2333/70596
Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
-
公开(公告)号：US20170342134A1
公开(公告)日：2017-11-30
申请号：US15638820
申请日：2017-06-30
Applicant: AIMM THERAPEUTICS B.V.
Inventor： Tim Beaumont , Etsuko Yasuda
IPC: C07K16/10 , G01N33/569 , A61K39/00
CPC classification number: C07K16/1027 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/30 , C07K2317/34 , C07K2317/76 , G01N33/56983 , G01N2333/135
Abstract: The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
-
公开(公告)号：US09718876B2
公开(公告)日：2017-08-01
申请号：US14359291
申请日：2012-11-16
Applicant: AIMM Therapeutics B.V.
Inventor： Tim Beaumont , Etsuko Yasuda
IPC: C07K16/10 , G01N33/569 , A61K39/00
CPC classification number: C07K16/1027 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/30 , C07K2317/34 , C07K2317/76 , G01N33/56983 , G01N2333/135
Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.024 seconds)
